Cereblon isoforms and their use as biomarkers for therapeutic treatment
US9587281B2 · kind B2 · utility
4Cited by
58References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 12, 2015 |
| Grant date | Mar 7, 2017 |
| Priority date | — |
| Expiry date | Feb 12, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are cereblon isoforms and methods of their use as biomarkers for treating a disease, disorder, or condition with a treatment compound, e.g., thalidomide, lenalidomide, pomalidomide, 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-dione, or (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.